Teva México

What Teva México does

Teva México (legal entity: Teva Pharma México, S.A. de C.V.) is a wholly-owned subsidiary of Teva Pharmaceutical Industries Ltd (NYSE: TEVA), an Israeli-headquartered global pharmaceutical group founded in 1901. The Mexico entity produces and commercializes generic medications, specialty pharmaceuticals, and active pharmaceutical ingredients (APIs), serving patients, healthcare providers, and institutions across the Mexican market. The subsidiary operates two main manufacturing sites: the Planta Guadalajara in Zapopan, Jalisco, which produces finished dosage forms including oral solids using recently upgraded state-of-the-art technology, and the TAPI plant in Lerma, Estado de México, which operates 14 production suites producing high-potency APIs spanning hormonal steroids, oncological products, synthetic antibiotics, respiratory APIs, and neuromuscular blockers.

The company's commercial portfolio spans a generic catalog leveraging the parent's more than 1,800-molecule library across nearly all therapeutic areas, alongside specialty offerings in oncology, neurosciences, pain management, and cardiometabolic conditions. Distribution occurs through three channels: traditional retail pharmacies (where products require medical prescription), direct sales to hospitals and healthcare institutions, and the proprietary TiendaTeva online storefront. The TAPI facility holds approvals from nine major regulatory agencies (COFEPRIS, FDA, MHRA, PMDA, TGA, KFDA, MCC, EDQM, DHA), enabling export-grade API production and providing the operational backbone for vertical integration.

Teva México's revenue model is prescription-driven pharmaceutical sales — essentially a one-time-per-unit transaction model rather than subscription or licensing — and revenue is not separately disclosed from the parent's consolidated reporting. The subsidiary is governed by the parent's global frameworks, including participation in CETIFARMA (Mexico) and IFPMA (international) ethics organizations, which has supported recognition as one of the most ethical pharmaceutical companies for more than two consecutive years. Patient-engagement assets include the Historias que acompañan storytelling platform and the recurring Humanizando la Salud awards program.

Name

Teva México

Legal name

Teva Pharma México, S.A. de C.V.

Website

https://tevamexico.com.mx

Company type

Private

Founded year

1901

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Teva México is a wholly-owned subsidiary of Teva Pharmaceutical Industries Ltd that manufactures and distributes generic and specialty pharmaceuticals plus active pharmaceutical ingredients in Mexico through two manufacturing sites (Guadalajara and Lerma TAPI), serving patients, pharmacies, hospitals, and institutions.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Medicinal and Botanical Manufacturing (325411)

SIC

Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH)

akta.pro secondary industry

Generic ANDA/Regulatory Affairs & Submissions (HLAIABAJ)

Keywords

• Generic pharmaceuticals
• Specialty medications
• Active pharmaceutical ingredients
• Drug manufacturing
• Pharmaceutical products

Headquarters

HQ city

Mexico City

HQ country

Mexico

HQ region

Latin America

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Generic Pharmaceuticals: Production and sale of generic medications including tablets, capsules, ointments, creams, and liquids across various therapeutic areas and dosage ranges with complex delivery systems
2. Specialty Pharmaceuticals: Innovative specialty medications in key therapeutic areas including oncology, neuroscience, pain management, and cardiometabolic conditions
3. Active Pharmaceutical Ingredients (APIs): Manufacturing and supply of active pharmaceutical ingredients including hormonal steroids, oncological products, respiratory APIs, and neuromuscular blockers through TAPI division

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels7 records

Core offering

Teva México produces generic drugs, specialty pharmaceuticals, and active pharmaceutical ingredients (APIs) for the Mexican and export markets. The company operates two manufacturing facilities — Planta Guadalajara in Zapopan for finished dosage forms (oral solids, tablets, capsules) and the TAPI plant in Lerma for high-potency active pharmaceutical ingredients — and markets its portfolio across therapeutic areas including oncology, neuroscience, pain management, and cardiometabolic conditions through pharmacies, healthcare institutions, and its TiendaTeva online store.

Product overview

Teva México operates as a pharmaceutical manufacturing and commercialization company with two primary production sites: Planta Guadalajara in Zapopan, Jalisco (manufacturing finished dosage forms including oral solids) and TAPI in Lerma, Estado de México (manufacturing high-potency active pharmaceutical ingredients). The company offers a broad portfolio of generic medications across more than 1,800 molecules in nearly all therapeutic areas and dosage forms, alongside specialized therapeutic divisions covering Alta Especialidad (oncology), Neurociencias (neurosciences), Dolor (pain), and Cardiometabólico conditions. Patient-facing programs include Historias que Acompañan (a patient community platform) and the Humanizando la Salud awards initiative. The company is governed by global Teva operations spanning approximately 34,000 employees across 49 manufacturing plants and 22 R&D centers.

Differentiator

Problem solved

Functional benefit

Brands

• Historias que acompañan: Patient storytelling program that shares inspirational stories of patients living with chronic diseases
• Humanizando la Salud

Products and services

• Medicamentos Genéricos Teva Teva's generic pharmaceutical product line, spanning more than 1,800 molecules across nearly all therapeutic areas and dosage forms including tablets, capsules, ointments, creams, and liquids. Produced at approximately 120 billion tablets and capsules per year across over 70 manufacturing centers worldwide, serving patients and healthcare providers seeking high-quality, affordable off-patent medications.
• TAPI — Ingredientes Farmacéuticos Activos (APIs) Teva Active Pharmaceutical Ingredients (TAPI) product line, manufactured at the Lerma, Estado de México facility with 14 production suites. Supplies high-potency APIs in low and medium volumes across categories including hormonal steroids, anti-inflammatory steroids, oncological products, synthetic antibiotics, respiratory APIs, and neuromuscular blockers. Serves the parent group and external customers with timely generic product launches.
• Alta Especialidad (Oncology Therapeutics) Specialty oncology portfolio providing innovative and cost-effective therapeutic solutions for leukemia, lymphomas, multiple myeloma, myelodysplastic syndromes, and supportive care therapies. Targeted at hematological malignancies with high-specialty offerings.
• Neurociencias (Neuroscience Therapeutics) Neuroscience therapeutic portfolio supplying medications for degenerative conditions including Alzheimer's disease, multiple sclerosis, migraine, and Parkinson's disease. Targets patients with degenerative neurological and central nervous system conditions.
• Dolor (Pain Therapeutics) Pain management therapeutic portfolio with a broad offering for treating osteoarthrosis, acute pain, and rheumatoid arthritis. Addresses musculoskeletal conditions through multiple formulations.
• Cardiometabólico (Cardiometabolic Therapeutics) Cardiometabolic therapeutic portfolio, one of the most comprehensive in the market, including therapies for arterial hypertension, cholesterol, and vascular diseases. Addresses cardiovascular and metabolic diseases.

Named customers1 record

Segments5 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Two partnerships are on record, tiered core.

• CETIFARMAcoreOthersTeva México participates in CETIFARMA (Centro de Estudios sobre Ética y Transparencia de la Industria Farmacéutica), a national organization promoting ethical standards and self-regulation within the pharmaceutical industry in Mexico. This affiliation reinforces Teva's operating framework and contributes to ensuring products reach Mexican families with quality and safety.
• IFPMAcoreOthersTeva México participates in IFPMA (International Federation of Pharmaceutical Manufacturers & Associations), an international organization promoting ethical standards and responsible behavior in the pharmaceutical industry globally. This affiliation reinforces Teva's commitment to integrity and responsible innovation.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Teva Pharmaceutical Industries Ltd. Parent company of Teva México and one of the world's largest generic pharmaceutical manufacturers, offering the same generic, specialty, and API portfolio globally. Direct peer because it produces and sells the same molecules through the same business model, only at global scale and through other subsidiaries.
• Aurobindo Pharma: India-headquartered global generic and API manufacturer with a large molecule portfolio, vertical API integration, and US-FDA-inspected facilities. Direct peer on manufacturing scale, regulatory breadth, and Mexican/Latin American distribution.
• Sandoz Group AG: Novartis's generics and biosimilars division, headquartered in Switzerland with global manufacturing and Mexican commercial presence. Directly comparable as a top-tier global generic pharmaceutical manufacturer with a comparable molecule breadth and pharmaceutical manufacturing footprint.
• Laboratorios Silanes S.A. de C.V. Mexico-based pharmaceutical company producing branded generics, specialty products, and biologics across cardiometabolic, CNS, and other therapeutic areas. Direct peer given comparable Mexican-market focus, generic manufacturing model, and overlap in cardiometabolic and neuroscience portfolios.
• Pisa Farmacéutica: One of the largest Mexican pharmaceutical groups, manufacturing generics, specialty products, and IV solutions with strong hospital channel presence. Direct competitor across generic manufacturing, oncology/pain therapeutic areas, and Mexican institutional sales.
• Viatris Inc. Global healthcare company formed from the merger of Mylan and Pfizer's Upjohn division, focused on generics, biosimilars, and branded medicines across therapeutic areas. Direct peer with overlapping generic, specialty, and API activities and broad international regulatory footprint comparable to Teva's.
• Apotex Inc. Canadian-headquartered global generic pharmaceutical manufacturer producing finished dosage forms and APIs across a broad therapeutic portfolio. Direct peer because of comparable generic manufacturing, API integration, and presence in the Mexican market through local distribution.
• Dr. Reddy's Laboratories: India-based global pharmaceutical company producing generics, APIs, and biosimilars across therapeutic areas. Direct peer given its integrated API-to-finished-dose model, similar molecule breadth, and established Mexican/Latin American distribution presence.
• Liomont S.A. de C.V. Major Mexico-based pharmaceutical manufacturer of generic and specialty products, including injectables and sterile formats. Direct competitor in the Mexican market with overlapping generic portfolio and similar distribution through pharmacies and the public sector.
• Sun Pharmaceutical Industries: India-headquartered global specialty and generic pharmaceutical company with manufacturing in multiple jurisdictions and broad therapeutic coverage. Direct peer with overlapping generic manufacturing scale, specialty pipeline, and growing presence in Latin American markets.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/TevaMx
• LinkedInlinkedin.com/company/tevamx
• Instagraminstagram.com/tevamexico
• TikToktiktok.com/@tevamexico
• Xx.com/tevamexico

Compliance15 records

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Teva México